Eli Lilly’s once-weekly insulin, efsitora alfa, has shown promising results in two pivotal studies, being comparable to once-daily insulin in treating type 2 diabetes. The fusion protein aims to provide more stable glucose levels over a week, with positive outcomes in reducing hemoglobin A1C levels. This development brings the experimental insulin closer to competing with Novo Nordisk’s already available product, icodec. Lilly plans to share detailed results from the Phase 3 studies at an upcoming congress and in a peer-reviewed journal. Novo Nordisk has faced FDA rejection for its icodec submission due to concerns about hypoglycemia rates and manufacturing processes.
Source link
Eli Lilly Moves Closer to Bringing Diabetes Patients a Once-Weekly Insulin Alternative
